We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biosimilars, Generics to Slow Overall Pace of Growth in U.S. Drug Spending This Year
Biosimilars, Generics to Slow Overall Pace of Growth in U.S. Drug Spending This Year
Generics and biosimilars will slow the overall pace of drug spending growth this year, even though U.S. prescription drug spending is slated to rise by 4 to 6 percent year-over-year in 2022.